EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans

Keiko Komatsuzaki, Hiroki Kageshima, Yuki Sekino, Yasuhiro Suzuki, Tsukasa Ugajin, Meiyo Tamaoka, Ryoichi Hanazawa, Akihiro Hirakawa, Yasunari Miyazaki

Allergology International · 2024

DOI: 10.1016/j.alit.2023.10.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergology International, 2024. Verfasst von Keiko Komatsuzaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: komatsuzaki.hsc@tmd.ac.jp. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Seasonal, Food Hypersensitivity, Fluorocarbons, Mannans. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tokyo Medical and Dental University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Allergen immunotherapy (AIT) is the only disease-modifying treatment for immunoglobulin (Ig) E-mediated allergy. Owing to the high prevalence and early onset of hay fever and pollen-food allergy syndrome (PFAS), a safer and simpler treatment method than conventional AIT is needed. To develop a local nasal immunotherapy using an ointment containing hypoallergenic pollen and assess its efficacy in mice and healthy humans. METHODS: Hypoallergenicity was achieved by combining pollen and galactomannan through the Maillard reaction to create birch pollen-galactomannan conjugate (BP-GMC). The binding of galactomannan to Bet v 1 was confirmed using electrophoresis and Western blotting (WB). Binding of specific IgE antibodies to BP-GMC was verified using enzyme-linked immunosorbent assay (ELISA) and basophil activation test (BAT). The localization of BP-GMC absorption was confirmed using a BALB/c mouse model. BP-GMC mixed with white petrolatum was intranasally administered to 10 healthy individuals (active drugs, 8; placebo, 2) for 14 days. RESULTS: In electrophoresis and WB, no 17-kDa band was observed. In ELISA and BAT, BP-GMC did not react to specific IgE but was bound to IgA and IgG. In the mouse model, BP-GMC was detected in nasopharyngeal-associated lymphoid tissues. In the active drug group, the salivary-specific IgA level significantly increased on day 15 (p = 0.0299), while the serum-specific IgG level significantly increased on day 85 (p = 0.0006). CONCLUSIONS: The BP-GMC ointment rapidly produced antagonistic antibodies against IgE; it is safe and easy to use and might serve as a therapeutic antigen for hay fever and PFAS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, Allergic, SeasonalFood HypersensitivityFluorocarbonsMannansHumansAnimalsMiceAllergensBetulaAntigens, PlantOintmentsPollenImmunoglobulin EDesensitization, ImmunologicImmunoglobulin GImmunoglobulin AGalactose

Stichwörter der Autor:innen

Allergen immunotherapyBirch pollen-galactomannan conjugate ointmentHay feverLocal nasal immunotherapyPollen-food allergy syndrome

Substanzen

AllergensgalactomannanAntigens, PlantOintmentsImmunoglobulin EImmunoglobulin GImmunoglobulin AFluorocarbonsGalactoseMannans

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: komatsuzaki.hsc@tmd.ac.jp.
  • Bio & Healthcare Business Division, Wako Filter Technology Co., Ltd., Ibaraki, Japan.
  • Department of Otorhinolaryngology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Department of Dermatology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Department of Clinical Biostatistics, Tokyo Medical and Dental University, Tokyo, Japan.

Förderung

  • Tokyo Medical and Dental University

Zitieren

APA

Komatsuzaki, K., Kageshima, H., Sekino, Y., Suzuki, Y., Ugajin, T., Tamaoka, M., Hanazawa, R., Hirakawa, A., & Miyazaki, Y. (2024). Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans. Allergology International. https://doi.org/10.1016/j.alit.2023.10.007

Vancouver

Komatsuzaki K, Kageshima H, Sekino Y, Suzuki Y, Ugajin T, Tamaoka M, et al. Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans. Allergology International. 2024. doi:10.1016/j.alit.2023.10.007

BibTeX
@article{Komatsuzaki2024,
  author = {Komatsuzaki, Keiko and Kageshima, Hiroki and Sekino, Yuki and Suzuki, Yasuhiro and Ugajin, Tsukasa and Tamaoka, Meiyo and Hanazawa, Ryoichi and Hirakawa, Akihiro and Miyazaki, Yasunari},
  title = {Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans},
  journal = {Allergology International},
  year = {2024},
  doi = {10.1016/j.alit.2023.10.007}
}
Kostenlos starten →